The navigation guide—evidence-based medicine meets environmental health: Integration of animal and human evidence for PFOA effects on fetal growth

Environmental Health Perspectives

Volumn 122, Issue 10, 2014, Pages 1040-1051

  Lam, Juleen ^a   Koustas, Erica ^a   Sutton, Patrice ^b   Johnson, Paula I ^b   Atchley, Dylan S ^b   Sen, Saunak ^c   Robinson, Karen A ^d,e   Axelrad, Daniel A ^a   Woodruff, Tracey J ^b  

^a U S ENVIRONMENTAL PROTECTION AGENCY   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d JOHNS HOPKINS UNIVERSITY   (United States)

^e JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PERFLUOROOCTANOIC ACID; FLUOROCARBON; OCTANOIC ACID DERIVATIVE; POLLUTANT;

BIRTH WEIGHT; DECISION MAKING; ENVIRONMENTAL EXPOSURE; ENVIRONMENTAL HEALTH; EVIDENCE BASED MEDICINE; EXPERIMENTAL ANIMAL WELFARE; FETUS DEVELOPMENT; FETUS GROWTH; HUMAN; METHODOLOGY; NONHUMAN; OUTCOME ASSESSMENT; PREGNANCY OUTCOME; REVIEW; RISK ASSESSMENT; SENSITIVITY ANALYSIS; SYSTEMATIC REVIEW; ADVERSE EFFECTS; ANIMAL; DRUG EFFECTS; FEMALE; META ANALYSIS; POLLUTANT; PREGNANCY; TOXICITY;

ANIMALS; BIRTH WEIGHT; CAPRYLATES; ENVIRONMENTAL HEALTH; ENVIRONMENTAL POLLUTANTS; EVIDENCE-BASED MEDICINE; FEMALE; FETAL DEVELOPMENT; FLUOROCARBONS; HUMANS; MATERNAL EXPOSURE; PREGNANCY;

EID: 84907612282     PISSN: 00916765     EISSN: 15529924     Source Type: Journal    
DOI: 10.1289/ehp.1307923     Document Type: Review

References (86)

1. Adami HO, Berry SC, Breckenridge CB, Smith LL, Swenberg JA, Trichopoulos D, et al. 2011. Toxicology and epidemiology: improving the science with a framework for combining toxicological and epidemiological evidence to establish causal inference. Toxicol Sci 122:223–234.
2. Antman EM, Lau J, Kupelnick B, Mosteller F, Chalmers TC. 1992. A comparison of results of meta-analyses of randomized control trials and recommendations of clinical experts. Treatments for myocardial infarction. JAMA 268:240–248.
3. Apelberg BJ, Goldman LR, Calafat AM, Herbstman JB, Kuklenyik Z, Heidler J, et al. 2007. Determinants of fetal exposure to polyfluoroalkyl compounds in Baltimore, Maryland. Environ Sci Technol 41:3891–3897.
4. Arbuckle TE, Kubwabo C, Walker M, Davis K, Lalonde K, Kosarac I, et al. 2012. Umbilical cord blood levels of perfluoroalkyl acids and polybrominated flame retardants. Int J Hyg Environ Health 216:184–194.
5. Balshem H, Helfand M, Schünemann HJ, Oxman AD, Kunz R, Brozek J, et al. 2011. GRADE guidelines: 3. Rating the quality of evidence. J Clin Epidemiol 64:401–406.
6. Bebarta V, Luyten D, Heard K. 2003. Emergency medicine animal research: does use of randomization and blinding affect the results? Acad Emerg Med 10:684–687.
7. Bero L. 2013. Why the Cochrane risk of bias tool should include funding source as a standard item [Editorial]. Cochrane Database Syst Rev 12:ED000075.
8. Budescu DV, Por HH, Broomell SB. 2012. Effective communication of uncertainty in the IPCC reports. Climatic Change 113:181–200.
9. California Office of Environmental Health Hazard Assessment. 2011. A Chemical Listed Effective October 28, 2011 as Known to the State of California to Cause Cancer Tris(1,3 dichloro-2-propyl) Phosphate (TDCPP) (CAS No. 13674-87-8). Available: http://oehha.ca.gov/prop65/prop65_list/102811list.html [accessed 20 February 2014].
10. California Office of Environmental Health Hazard Assessment. 2013. Safe Drinking Water and Toxic Enforcement Act of 1986. Available: http://www.oehha.org/prop65/law/P65law72003.html [accessed 20 February 2014].
11. Deeks JJ, Higgins JPT, Altman DG, eds. 2011. Chapter 9: Analysing data and undertaking meta-analyses. In: Cochrane Handbook for Systematic Reviews of Interventions, Version 5.1.0 (Higgins JPT, Green S, eds). Available: http://www.cochrane-handbook.org [accessed 15 April 2013].
12. DerSimonian R, Laird N. 1986. Meta-analysis in clinical trials. Control Clin Trials 7:177–188.
13. DeWitt JC, Shnyra A, Badr MZ, Loveless SE, Hoban D, Frame SR, et al. 2009. Immunotoxicity of perfluorooctanoic acid and perfluorooctane sulfonate and the role of peroxisome proliferator-activated receptor alpha. Crit Rev Toxicol 39:76–94.
14. DuMouchel WH, Harris JE. 1983. Bayes methods for combining the results of cancer studies in humans and other species. J Am Stat Assoc 78:293–308.
15. Fox DM. 2010. The Convergence of Science and Governance: Research, Health Policy, and American States. Berkeley, CA:University of California Press.
16. Fromme H, Mosch C, Morovitz M, Alba-Alejandre I, Boehmer S, Kiranoglu M, et al. 2010. Pre- and postnatal exposure to perfluorinated compounds (PFCs). Environ Sci Technol 44:7123–7129.
17. Gee D. 2008. Establishing evidence for early action: the prevention of reproductive and developmental harm. Basic Clin Pharmacol Toxicol 102:257–266.
18. GRADE Working Group. 2012. GRADE Working Group Homepage. Available: http://www.gradeworkinggroup.org/ [accessed 13 September 2012].
19. Guyatt GH, Oxman AD, Kunz R, Woodcock J, Brozek J, Helfand M, et al. 2011a. GRADE guidelines: 8. Rating the quality of evidence—indirectness. J Clin Epidemiol 64:1303–1310.
20. Guyatt GH, Oxman AD, Kunz R, Woodcock J, Brozek J, Helfand M, et al. 2011b. GRADE guidelines: 7. Rating the quality of evidence—inconsistency. J Clin Epidemiol 64:1294–1302.
21. Guyatt GH, Oxman AD, Montori V, Vist G, Kunz R, Brozek J, et al. 2011c. GRADE guidelines: 5. Rating the quality of evidence—publication bias. J Clin Epidemiol 64:1277–1282.
22. Guyatt GH, Oxman AD, Sultan S, Glasziou P, Akl EA, Alonso-Coello P, et al. 2011d. GRADE guidelines: 9. Rating up the quality of evidence. J Clin Epidemiol 64:1311-1316.
23. Guyatt GH, Oxman AD, Vist G, Kunz R, Brozek J, Alonso-Coello P, et al. 2011e. GRADE guidelines: 4. Rating the quality of evidence—study limitations (risk of bias). J Clin Epidemiol 64:407–415.
24. Guyatt GH, Oxman AD, Vist GE, Kunz R, Falck-Ytter Y, Alonso-Coello P, et al. 2008. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ 336:924–926.
25. Halldorsson TI, Rytter D, Haug LS, Bech BH, Danielsen I, Becher G, et al. 2012. Prenatal exposure to perfluorooctanoate and risk of overweight at 20 years of age: a prospective cohort study. Environ Health Perspect 120:668–673; doi:10.1289/ehp.1104034.
26. Hekster FM, Laane RW, de Voogt P. 2003. Environmental and toxicity effects of perfluoroalkylated substances. Rev Environ Contam Toxicol 179:99–121.
27. Higgins JPT, Green S. 2011. Cochrane Handbook for Systematic Reviews of Interventions, Version 5.1.0. Available: http://www.cochrane-handbook.org [accessed 8 September 2014].
28. Higgins JPT, Thompson SG, Deeks JJ, Altman DG. 2003. Measuring inconsistency in meta-analyses. BMJ 327:557–560.
29. IARC (International Agency for Research on Cancer). 2006. IARC Monographs on the Evaluation of Carcinogenic Risks to Humans: Preamble. Available: http://monographs.iarc.fr/ENG/Preamble/index.php [accessed 8 September 2014].
30. Institute of Medicine. 2007. Preterm Birth: Causes, Consequences, and Prevention. Washington, DC:National Academies Press. Available: http://books.nap.edu/openbook.php?record_id=11622 [accessed 8 September 2014].
31. Institute of Medicine, Eden J, Wheatley B, McNeil B, Sox H. 2008. Knowing What Works in Health Care: A Roadmap for the Nation. Washington, DC:National Academies Press. Available: http://www.nap.edu/catalog.php?record_id=12038 [accessed 8 September 2014].
32. Jensen AA, Leffers H. 2008. Emerging endocrine disrupters: perfluoroalkylated substances. Int J Androl 31:161–169.
33. Johnson PI, Sutton P, Atchley DS, Koustas E, Lam J, Sen S, et al. 2014. The Navigation Guide—evidence-based medicine meets environmental health: systematic review of human evidence for PFOA effects on fetal growth. Environ Health Perspect 122:1028- 1039; doi:10.1289/ehp.1307893.
34. Jones DR, Peters JL, Rushton L, Sutton AJ, Abrams KR. 2009. Interspecies extrapolation in environmental exposure standard setting: a Bayesian synthesis approach. Regul Toxicol Pharmacol 53:217–225.
35. Kennedy GL Jr, Butenhoff JL, Olsen GW, O’Connor JC, Seacat AM, Perkins RG, et al. 2004. The toxicology of perfluorooctanoate. Crit Rev Toxicol 34:351–384.
36. Kim S, Choi K, Ji K, Seo J, Kho Y, Park J, et al. 2011. Trans-placental transfer of thirteen perfluorinated compounds and relations with fetal thyroid hormones. Environ Sci Technol 45:7465–7472.
37. Kim SK, Lee KT, Kang CS, Tao L, Kannan K, Kim KR, et al. 2011. Distribution of perfluorochemicals between sera and milk from the same mothers and implications for prenatal and postnatal exposures. Environ Pollut 159:169–174.
38. Kimmel CA, Holson JF, Hogue CJ, Carlo G. 1984. Reliability of Experimental Studies for Predicting Hazards to Human Development. NCTR Technical Report for Experiment 6015. Jefferson, AR:National Center for Toxicological Research.
39. Koustas E, Lam J, Sutton P, Johnson PI, Atchley DS, Sen S, et al. 2014. The Navigation Guide—evidence-based medicine meets environmental health: systematic review of nonhuman evidence for PFOA effects on fetal growth. Environ Health Perspect 122:1015–1027; doi:10.1289/ehp.1307177.
40. Krauth D, Anglemyer A, Philipps R, Bero L. 2014. Nonindustry-sponsored preclinical study on statins yield greater efficacy estimates than industry-sponsored studies: a meta analysis. PLOS Biol 12(1):e1001770; doi:10.1371/journal.pbio.1001770.
41. Krauth D, Woodruff TJ, Bero L. 2013. Instruments for assessing risk of bias and othermethodological criteria of published animal studies: a systematic review. Environ Health Perspect 121:985–992; doi:10.1289/ehp.1206389.
42. Kudo N, Kawashima Y. 2003. Toxicity and toxicokinetics of perfluorooctanoic acid in humans and animals. J Toxicol Sci 28:49–57.
43. Landis SC, Amara SG, Asadullah K, Austin CP, Blumenstein R, Bradley EW, et al. 2012. A call for transparent reporting to optimize the predictive value of preclinical research. Nature 490:187–191.
44. Lau C, Anitole K, Hodes C, Lai D, Pfahles-Hutchens A, Seed J. 2007. Perfluoroalkyl acids: a review of monitoring and toxicological findings. Toxicol Sci 99:366–394.
45. Lau C, Butenhoff JL, Rogers JM. 2004. The developmental toxicity of perfluoroalkyl acids and their derivatives. Toxicol Appl Pharmacol 198:231–241.
46. Lindstrom AB, Strynar MJ, Libelo EL. 2011. Polyfluorinated compounds: past, present, and future. Environ Sci Technol 45:7954–7961.
47. Loccisano AE, Longnecker MP, Campbell JL Jr, Andersen ME, Clewell HJ III. 2013. Development of PBPK models for PFOA and PFOS for human pregnancy and lactation life stages. J Toxicol Environ Health A 76:25–57.
48. Lundh A, Sismondo S, Lexchin J, Busuioc OA, Bero L. 2012. Industry sponsorship and research outcome. Cochrane Database Syst Rev 12:MR000033; doi:10.1002/14651858.MR000033.pub2.
49. Macleod MR, O’Collins T, Howells DW, Donnan GA. 2004. Pooling of animal experimental data reveals influence of study design and publication bias. Stroke 35:1203- 1208.
50. Mondal D, Lopez-Espinosa MJ, Armstrong B, Stein CR, Fletcher T. 2012. Relationships of perfluorooctanoate and perfluorooctane sulfonate serum concentrations between mother–child pairs in a population with perfluorooctanoate exposure from drinking water. Environ Health Perspect 120:752–757; doi:10.1289/ehp.1104538.
51. Monroy R, Morrison K, Teo K, Atkinson S, Kubwabo C, Stewart B, et al. 2008. Serum levels of perfluoroalkyl compounds in human maternal and umbilical cord blood samples. Environ Res 108:56–62.
52. National Toxicology Program. 2013. OHAT Implementation of Systematic Review. Available: http://ntp.niehs.nih.gov/?objectid=960B6F03-A712-90CB 8856221E90EDA46E [accessed 7 November 2013].
53. Nolan LA, Nolan JM, Shofer FS, Rodway NV, Emmett EA. 2009. The relationship between birth weight, gestational age and perfluorooctanoic acid (PFOA)-contaminated public drinking water. Reprod Toxicol 27:231–238.
54. NRC (National Research Council). 2007. Toxicity Testing in the 21st Century: A Vision and a Strategy. Washington, DC:National Academies Press. Available: http://www.nap.edu/catalog.php?record_id=11970 [accessed 8 September 2014].
55. NRC (National Research Council). 2009. Science and Decisions: Advancing Risk Assessment. Washington, DC:National Academies Press. Available: http://www.nap.edu/catalog.php?record_id=12209 [accessed 8 September 2014].
56. NRC (National Research Council). 2011. Review of the Environmental Protection Agency’s Draft IRIS Assessment of Formaldehyde. Washington, DC:National Academies Press. Available: http://www.nap.edu/catalog.php?record_id=13142 [accessed 8 September 2014].
57. NRC (National Research Council). 2014. Review of EPA’s Integrated Risk Information System (IRIS) Process. Washington, DC:National Academies Press. Available: http://www.nap.edu/catalog.php?record_id=18764 [accessed 8 September 2014].
58. Olsen GW, Butenhoff JL, Zobel LR. 2009. Perfluoroalkyl chemicals and human fetal development: an epidemiologic review with clinical and toxicological perspectives. Reprod Toxicol 27:212–230.
59. Peters JL, Rushton L, Sutton AJ, Jones DR, Abrams KR, Mugglestone MA. 2005. Bayesian methods for the cross–design synthesis of epidemiological and toxicological evidence. J R Stat Soc Ser C Appl Stat 54:159–172.
60. Post GB, Cohn PD, Cooper KR. 2012. Perfluorooctanoic acid (PFOA), an emerging drinking water contaminant: a critical review of recent literature. Environ Res 116:93-117.
61. Prevedouros K, Cousins IT, Buck RC, Korzeniowski SH. 2006. Sources, fate and transport of perfluorocarboxylates. Environ Sci Technol 40:32–44.
62. Rennie D, Chalmers I. 2009. Assessing authority. JAMA 301:1819–1821.
63. Rooney AA, Boyles AL, Wolfe MS, Bucher JR, Thayer KA. 2014. Systematic review and evidence integration for literature-based environmental health science assessments. Environ Health Perspect 122:711–718; doi:10.1289/ehp.1307972.
64. Savitz DA. 2007. Biomarkers of perfluorinated chemicals and birth weight [Editorial]. Environ Health Perspect 115:A528–A529; doi:10.1289/ehp.10923.
65. Savitz DA, Stein CR, Bartell SM, Elston B, Gong J, Shin HM, et al. 2012. Perfluorooctanoic acid exposure and pregnancy outcome in a highly exposed community. Epidemiology 23:386–392.
66. Sawaya GF, Guirguis-Blake J, LeFevre M, Harris R, Petitti D. 2007. Update on the methods of the U.S. Preventive Services Task Force: estimating certainty and magnitude of net benefit. Ann Intern Med 147:871–875.
67. Simpkins JW, Swenberg JA, Weiss N, Brusick D, Eldridge JC, Stevens JT, et al. 2011. Atrazine and breast cancer: a framework assessment of the toxicological and epidemiological evidence. Toxicol Sci 123:441–459.
68. Steenland K, Fletcher T, Savitz DA. 2010. Epidemiologic evidence on the health effects of perfluorooctanoic acid (PFOA). Environ Health Perspect 118:1100–1108; doi:10.1289/ehp.0901827.
69. Stein CR, Savitz DA, Dougan M. 2009. Serum levels of perfluorooctanoic acid and perfluorooctane sulfonate and pregnancy outcome. Am J Epidemiol 170:837–846.
70. Sterne JAC. 2013. Why the Cochrane risk of bias tool should not include funding source as a standard item [Editorial]. Cochrane Database Syst Rev 12:ED000076.
71. Sterne JAC, Sutton AJ, Ioannidis JP, Terrin N, Jones DR, Lau J, et al. 2011. Recommendations for examining and interpreting funnel plot asymmetry in meta-analyses of randomised controlled trials. BMJ 343:d4002; doi:10.1136/bmj.d4002.
72. Taubes G. 1995. Epidemiology faces its limits. Science 269:164–169.
73. UCSF (University of California, San Francisco) Program on Reproductive Health and the Environment. 2013. Clinical Practice & Policy: Navigation Guide. An Evidence-Based Medicine Methodology to Bridge the Gap Between Clinical and Environmental Health Sciences. Available: http://prhe.ucsf.edu/prhe/navigationguide.html [accessed 20 February 2014].
74. U.S. EPA (U.S. Environmental Protection Agency). 1991. Guidelines for Developmental Toxicity Risk Assessment. Available: http://cfpub.epa.gov/ncea/cfm/recordisplay.cfm?deid=23162#Download [accessed 27 February 2014].
75. U.S. EPA (U.S. Environmental Protection Agency). 1996. Guidelines for Reproductive Toxicity Risk Assessment. Available: http://www.epa.gov/raf/publications/pdfs/REPRO51.PDF [accessed 27 February 2014].
76. U.S. EPA (U.S. Environmental Protection Agency). 2012. Basic Information, Perfluorooctanoic acid (PFOA) and Fluorinated Telomers. Available: http://epa.gov/oppt/pfoa/pubs/pfoainfo.html#background [accessed 9 May 2013].
77. U.S. Food and Drug Administration. 2011. Advancing Regulatory Science at FDA: A Strategic Plan. Washington, DC:U.S. Food and Drug Administration. Available: http://www.fda.gov/downloads/scienceresearch/specialtopics/regulatoryscience/ucm268225.pdf [accessed 8 September 2014].
78. Verner M, Loccisano A, Yoon M, Wu H, McDougall R, Maisonet M, et al. 2014. The association between prenatal exposure to perfluoroalkyl substances (PFAS) and reduced birth weight: is glomerular filtration rate the underlying cause? [Abstract]. Abstract 89. Toxicologist 138(1):18.
79. Viechtbauer W. 2010. Conducting meta-analyses in R with the metafor package. J Stat Softw 36:1–48.
80. Viswanathan M, Ansari M, Berkman N, Chang S, Hartling L, McPheeters L, et al. 2012. Assessing the risk of bias of individual studies in systematic reviews of health care interventions. Agency for Healthcare Research and Quality Methods Guide for Comparative Effectiveness Reviews. AHRQ Publication No. 12-EHC047-EF. Available: http://effectivehealthcare.ahrq.gov/ehc/products/322/998/MethodsGuideforCERs_Viswa athan_IndividualStudies.pdf [accessed 8 September 2014].
81. White SS, Fenton SE, Hines EP. 2011. Endocrine disrupting properties of perfluorooctanoic acid. J Steroid Biochem Mol Biol 127:16–26.
82. Whittaker PG, Macphail S, Lind T. 1996. Serial hermatologic changes and pregnancy outcome. Obstet Gynecol 88(1):33–39.
83. Whitworth KW, Haug LS, Baird DD, Becher G, Hoppin JA, Skjaerven R, et al. 2012. Perfluorinated compounds in relation to birth weight in the Norwegian Mother and Child Cohort Study. Am J Epidemiol 175:1209–1216.
84. Woodruff TJ, Sutton P. 2014. The Navigation Guide: an improved method for translating environmental health science into better health outcomes. Environ Health Perspect 122:1007–1014; doi:10.1289/ehp.1307175.
85. Woodruff TJ, Sutton P, The Navigation Guide Work Group. 2011a. An evidence-based medicine methodology to bridge the gap between clinical and environmental health sciences. Health Aff (Millwood) 30:931–937.
86. Woodruff TJ, Zota AR, Schwartz JM. 2011b. Environmental chemicals in pregnant women in the United States: NHANES 2003–2004. Environ Health Perspect 119:878-885; doi:10.1289/ehp.1002727.